Research programme: cancer therapeutics - Sprint Biosciences/Unknown company

Drug Profile

Research programme: cancer therapeutics - Sprint Biosciences/Unknown company

Alternative Names: PIP4K2a inhibitors

Latest Information Update: 11 Jul 2016

Price : $50

At a glance

  • Originator Sprint Bioscience
  • Developer Unknown
  • Class Antineoplastics
  • Mechanism of Action 1-phosphatidylinositol 4-kinase modulators; Tumour protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 07 Jul 2016 Preclinical trials in Cancer in USA (unspecified route)
  • 07 Jul 2016 Phosphatidylinositol-5-phosphate 4-kinase type-2 alpha inhibitors licensed to an undisclosed US based company worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top